Gene ther­a­pies for the cats and dogs you love? Penn-part­nered Scout Bio just raised $20M to make it a re­al­i­ty

The gene ther­a­py rev­o­lu­tion that’s been sweep­ing through biotech isn’t just about hu­mans any­more. A Penn-part­nered biotech called Scout Bio has just picked up a $20 mil­lion round to step up its work on once-and-done ther­a­pies for com­mon pet ail­ments.

Co-found­ed by leg­endary gene ther­a­py pi­o­neer and Penn in­ves­ti­ga­tor James Wil­son, Scout is us­ing some fa­mil­iar AAV tech to go af­ter dis­eases like chron­ic kid­ney dis­ease, chron­ic pain and the in­flam­ma­to­ry skin con­di­tion atopic der­mati­tis.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.